Down 31% from Oct 27 to Nov 10.
Up 843% over the three years to Nov 9 while the S&P 500 rose 80%; down 31% since Oct 27.
The reasons, from its filings, with the timeline and its peers, for Pro members.
SLS's Quality Score fell 2 points on Tue, Nov 10, to -2. It closed away from its high of the day (2 chart checks stopped).
Follow SLS's trial news. Pro members can get an alert when SELLAS Life Sciences Group files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 92.0% more shares than a year ago |
| Latest filing | 10-Q, Aug 11 |
ReportExpected to report tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +4.7% on average. Past reports ›
Sat Dec 12: American Society of Hematology…Industry event · date confirmed.
After its last 4 reports it closed +4.7% on average, higher 2 of 4 times.
About 19 quarters
Director Katherine Bach Kalin bought 63,400 shares on Nov 19, 2025.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
SLS is #68 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 68 |
Expected to report Wed Nov 11, after the close (tomorrow).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily due to increases in manufacturing costs, clinical and regulatory consulting, and clinical trial expenses in preparation for a potential Biologics License Application (BLA) for GPS following the final analysis of the REGAL study.”
SLS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to increases in professional fees and non-cash stock-based compensation.”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 11, 2026 | +7.9% | +6.5% | +18.6% |
| May 12, 2026 | +21.0% | +25.1% | +45.4% |
| Mar 19, 2026 | +7.7% | -8.5% | -4.8% |
RSI 37.2, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: SLS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
“While we believe that our scientific knowledge, assets, development experience and ability to attract experienced commercial professionals provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, which either alone or together with their collaborative partners, have substantially greater resources than we have.”
SLS scores -2 today, which Breakaway calls Poor. It is #68 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 31% from Oct 27 to Nov 10. Cash lasts about 19 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
SLS scores -2 today, which Breakaway calls Poor (below zero). That is #68 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SLS's -2.
Expected to report Wed Nov 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. SLS closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.